Navigation Links
Anthera Completes Special Protocol Assessment With FDA and Receives EMEA Scientific Advice on Development Path Toward Varespladib Approval
Date:9/24/2008

SAN MATEO, Calif., Sept. 24 /PRNewswire/ -- Anthera Pharmaceuticals announced today they have reached agreement with the U.S. Food and Drug Administration (FDA) on a Phase 3 protocol for varespladib (A-002) in acute coronary syndrome (ACS) under the FDA's Special Protocol Assessment procedure. At the same time, the company received Scientific Advice from the European Medicines Agency (EMEA) on Anthera's European development strategy for varespladib. Guidance from both regulatory agencies regarding varespladib will be incorporated into Anthera's global registration program slated to start next year.

Anthera's Special Protocol Assessment supports a single, pivotal, Phase 3 trial evaluating varespladib, in combination with Lipitor(R) (atorvastatin) as first-line treatment within 96 hours of an ACS event. In the European Union, Anthera received Scientific Advice that supports a similar clinical development program and include the potential to also utilize varespladib as an adjunctive treatment in patients with stable coronary disease and elevated levels of LDL-C and total cholesterol.

"We are pleased that both agencies recognized the potential of varespladib's multiple therapeutic effects in patients with cardiovascular disease," said Paul Truex, President and Chief Executive Officer of Anthera Pharmaceuticals, Inc. "The anti-inflammatory effect and safety profile seen in the varespladib trials to date are very exciting and highlight the opportunity to help patients with recent coronary events."

"The regulatory clarity in the United States and Europe reinforces our confidence that we can efficiently deliver a novel therapeutic for patients with ACS," said Dr. Ursula Fritsch, Vice-President Global Regulatory and Compliance. "With this regulatory feedback, we have a clearly defined and reasonable development path to deliver a first in class therapeutic for ACS patients and individuals with hypercholesterolemia."

"The recent publication o
'/>"/>

SOURCE Anthera Pharmaceuticals
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Anthera Pharmaceuticals Advances Global Development Strategy for Varespladib in Patients With Acute Coronary Syndrome With the Initiation of FRANCIS Trial
2. DSMB Supports Continuation of Anthera Phase II Impacts Trial for the Prevention of Acute Chest Syndrome in Patients With Sickle Cell Disease
3. Anthera Enters Into Manufacturing Agreements for Varespladib in Preparation for Pivotal Phase III Trials
4. Anthera Announces Preliminary Positive Results From Once-Daily A-002 Phase II Cardiovascular Trial
5. Antheras A-001 Receives Orphan Drug Status for the Prevention of Acute Chest Syndrome in Patients With Sickle Cell Disease
6. Anthera Announces Positive Phase II Clinical Results From A-002 Cardiovascular Disease Trial
7. Anthera Announces Completion of Enrollment and Dosing in Phase II Trial of A-002 for the Treatment of Cardiovascular Disease
8. Arpida Completes Enrolment in Phase II "Intravenous-to-Oral" Switch Trial With Oral Iclaprim
9. Merck Serono Completes Enrollment in the REFLEX Trial of Rebif(R) in Patients at Risk of Developing Multiple Sclerosis
10. CuraGen Completes Enrollment in Phase II Trial of CR011-vcMMAE in Metastatic Melanoma
11. Human Genome Sciences Completes Enrollment in Second Phase 3 LymphoStat-B(R) Trial
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/2/2015)... -- Research and Markets ( http://www.researchandmarkets.com/research/sn8mlw/picture_archiving ) has announced the ... - Global Strategic Business Report" report to their offering. ... US, Canada , Japan ... , Latin America , and Rest of ... the period 2014 through 2020. Also, a seven-year historic analysis ...
(Date:6/2/2015)... ATLANTA , June 2, 2015 ... (CSTE) joins over 150 major food companies, retailers, ... White House Forum on Antibiotic Stewardship. CSTE is ... of antibiotic-resistant bacteria, detect resistant strains, preserve the ... spread of resistant infections. CSTE continues ...
(Date:6/2/2015)... 2015 San MediTech, the industry leader in ... (CGM) for diabetics, announced its plan to attend the ... Boston on June 5 th ... Glucose Monitoring System (DGMS). The company plans to show ... innovative technologies and advancements made by Chinese medical device ...
Breaking Medicine Technology:Picture Archiving and Communication Systems (PACS) - Global Strategic Business Report 2015: User Demand Favors Integrated RIS/PACS Solutions 2San MediTech Showcases Smart Glucose Management Cloud Database at 75th ADA 2San MediTech Showcases Smart Glucose Management Cloud Database at 75th ADA 3San MediTech Showcases Smart Glucose Management Cloud Database at 75th ADA 4
... Atrium Medical Corporation today announced that it is a ... by the Premier healthcare alliance . Premier ... one of 39 contracted suppliers to receive the Pinnacle Award. ... and their drive toward the mutual goal of providing clinical ...
... , Altair Semiconductor ( http://www.altair-semi.com ),the ... high performance 4G LTE,chipsets , announced today ... developed by AsiaTelco Technologies, achieved,download speeds of more ... in a live over-the-air demonstration requested by executives,from ...
Cached Medicine Technology:Atrium Honored by the Premier Healthcare Alliance for Operational Excellence 2Atrium Honored by the Premier Healthcare Alliance for Operational Excellence 3Altair Semiconductor Successfully Demonstrates its LTE Chipset Speeds and Service for China Mobile Executives 2Altair Semiconductor Successfully Demonstrates its LTE Chipset Speeds and Service for China Mobile Executives 3
(Date:6/3/2015)... 03, 2015 Foot and Ankle ... Casey Friske ( Clarksville Division ) was recently ... Symposium of Advanced Wound Care (SAWC) and the American ... Dan Davis. The Conference was held on April ... Center in San Antonio, TX. , Dr. Casey ...
(Date:6/3/2015)... Veatch Consulting Services is excited to announce ... for business in April 2006, they have made it ... clients. Each and every year they have worked diligently ... to say that they are off to a great ... added this year is the Customer Review site veatchconsultingreviews.weebly.com. ...
(Date:6/3/2015)... Israel (PRWEB) June 03, 2015 ... emergency mass-notification, multi-channel solutions, reported of its "behind-the-scenes" ... the past few months. Since March this year, ... has been inflicting the South-American country, putting millions ... ash and gas into the atmosphere. "evigilo's technology, ...
(Date:6/2/2015)... BALTIMORE, Md. – Ellarea Maria Cole ... wellness after being diagnosed with lupus. In spite of ... changes which enhance health, lupus and other autoimmune related ... for Wellness ,” she offers a holistic approach to ... provides an overview of some autoimmune diseases—especially lupus ...
(Date:6/2/2015)... 2015 The organic cotton market is ... an annual study conducted by Textile Exchange, an international ... The report, released today, encompasses extensive data about organic ... level and also takes the opportunity to celebrate those ... , The last several years have been complicated ...
Breaking Medicine News(10 mins):Health News:Foot and Ankle Specialists of the Mid-Atlantic, LLC Receives Award at the Spring 2015 Symposium of Advanced Wound Care Conference 2Health News:Veatch Consulting Services Is Breaking New Ground in Customer Satisfaction 2Health News:Veatch Consulting Services Is Breaking New Ground in Customer Satisfaction 3Health News:Thousands of Lives Saved, Millions Protected in Chile 2Health News:New book offers holistic approach in living with autoimmune diseases 2Health News:New book offers holistic approach in living with autoimmune diseases 3Health News:Organic Cotton Market Sees 10% Growth Following Three Years of Decline 2Health News:Organic Cotton Market Sees 10% Growth Following Three Years of Decline 3Health News:Organic Cotton Market Sees 10% Growth Following Three Years of Decline 4Health News:Organic Cotton Market Sees 10% Growth Following Three Years of Decline 5
... Bradford, from Oswestry, a patient with breast cancer in England ... are given free drug treatment// at a hospital. Local health ... the Shropshire Primary Care Trust. The patients in Shropshire have ... protest at the hospital on Monday. ,North Shropshire ...
... London, the cause of autism may now be explained due t ... not interacting well with other people. Weak links between brain areas ... situations as well as other people. ,The study ... an Autism Spectrum Disorder (ASD) while the other 16 did not. ...
... NHS trust failed to adequately supervise two doctors. Amit ... Hospital. It led to the death of the patient ... surgery. He suffered toxic shock syndrome. The hospital ... house officers. ,At a sentencing hearing at ...
... According to a new study of women with early stage, ... disease have been identified that may influence how patients are ... patients from 1988 to 2002 was reviewed by Cancer Research ... are risk factors for invasive disease and the pattern of ...
... Office (NHSO) has found that women aged above 35 are ... should annually undergo a Pap smear test for early detection ... is the most common type of cancer among women. ... scheme, has provided Pap smear services to 1.5 million women ...
... heart's largest artery, the aorta. Studies were going on to ... Johns Hopkins University// have successfully come up with the treatment. ... in recent studies for treating the genetic disorder. The ... appears to prevent the weakening of the heart's largest artery, ...
Cached Medicine News:Health News:Cancer Patients Protest For Free Drug Treatment 2Health News:Lack Of Communication Between Brain Areas Can Cause Autism 2
Do More with your Workforce. Technology That Makes Walkaway Automation a Reality. Engineered for Accurate Results. Multiple Levels of Control Reduce Contamination. Flexible Sample Preparation Platfor...
... 3100 system offers continuous, unattended operation ... separation and detection, and data analysis. ... and importing sample information, the operator ... Run command. The instrument requires no ...
RIA kit for the quantitative determination of autoantibodies to thyroid peroxidase (TPO) in serum....
... is,a no-extraction, solid-phase 125I,radioimmunoassay ... use in the quantitative,measurement ... for the,differential diagnosis of ... ovulation induction with,and without ...
Medicine Products: